We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.17%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$512M
AUM Growth
+$116M
Cap. Flow
+$1.26M
Cap. Flow %
0.25%
Top 10 Hldgs %
44.62%
Holding
138
New
35
Increased
30
Reduced
28
Closed
26

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$31.8M
2
BIIB icon
Biogen
BIIB
+$21.2M
3
NVS icon
Novartis
NVS
+$19M
4
PFE icon
Pfizer
PFE
+$13M
5
CELG
Celgene Corp
CELG
+$8.38M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$13M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.9M
4
MRK icon
Merck
MRK
+$9.86M
5
AKAO
Achaogen Inc
AKAO
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 4.38%
3 Communication Services 1.99%
4 Industrials 1.8%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
76
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.7M 0.33%
+15,000
New +$1.75M
AAP icon
77
Advance Auto Parts
AAP
$3.35B
$1.67M 0.33%
11,237
-4,822
-30% -$775K
PRQR icon
78
ProQR Therapeutics
PRQR
$243M
$1.65M 0.32%
330,000
+130,000
+65% +$572K
AXSM icon
79
Axsome Therapeutics
AXSM
$11.2B
$1.56M 0.31%
+401,000
New +$1.92M
EVOK
80
DELISTED
Evoke Pharma
EVOK
$1.55M 0.3%
+3,472
New +$1.42M
TSEM icon
81
Tower Semiconductor
TSEM
$24.8B
$1.55M 0.3%
67,155
-16,785
-20% -$368K
MGNX icon
82
MacroGenics
MGNX
$235M
$1.51M 0.3%
81,200
– –
FPRX
83
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.45M 0.28%
40,000
– –
OEF icon
84
CALL
iShares S&P 100 ETF
OEF
$20.1B
$1.39M 0.27%
100
-99,900
-100% -$10.3M
PDSB icon
85
PDS Biotechnology
PDSB
$38.4M
$1.37M 0.27%
7,500
– –
XENE icon
86
Xenon Pharmaceuticals
XENE
$6.06B
$1.31M 0.26%
328,029
– –
MA icon
87
Mastercard
MA
$502B
$1.3M 0.25%
11,525
+700
+6% +$76.7K
RARX
88
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.28M 0.25%
60,000
– –
FOMX
89
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.2M 0.23%
242,000
-100,000
-29% -$962K
ZGNX
90
DELISTED
Zogenix, Inc.
ZGNX
$1.08M 0.21%
+100,000
New +$1.01M
VTGN icon
91
VistaGen Therapeutics
VTGN
$9.89M
$1.07M 0.21%
18,137
– –
TMO icon
92
Thermo Fisher Scientific
TMO
$213B
$1.06M 0.21%
6,913
+550
+9% +$84.1K
PTN
93
Palatin Technologies
PTN
$13.7M
$952K 0.19%
2,325
– –
RPRX
94
DELISTED
Repros Therapeutics Inc.
RPRX
$935K 0.18%
778,800
-200,000
-20% -$250K
RCKT icon
95
Rocket Pharmaceuticals
RCKT
$340M
$804K 0.16%
100,441
– –
GNMX
96
DELISTED
Aevi Genomic Medicine Inc
GNMX
$753K 0.15%
405,000
-45,000
-10% -$204K
SEDG icon
97
SolarEdge
SEDG
$2.51B
$729K 0.14%
46,750
+20,547
+78% +$286K
ANAB icon
98
AnaptysBio
ANAB
$1.58B
$708K 0.14%
+25,500
New +$594K
ATXS
99
DELISTED
Astria Therapeutics
ATXS
$621K 0.12%
6,467
+1
+0% +$138
VIRX
100
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$513K 0.1%
3,571
– –
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sphera Funds Management held 138 positions worth $512M, up 29% from $395M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management's Q1 2017 filing shows 35 new, 30 increased, 28 reduced and 26 closed positions. Its largest new stake was Biogen: 75,000 shares worth $20.5M. The largest sale was Alexion Pharmaceuticals, an estimated $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 61% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2017 buy was Biogen: 75,000 shares worth $20.5M.
  • Sphera Funds Management added most to Shire pic in Q1 2017, an estimated $31.8M increase.
  • Sphera Funds Management's biggest Q1 2017 reduction was Teva Pharmaceuticals, cutting an estimated $11.9M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $13.8M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $512M portfolio in Q1 2017.
  • Sphera Funds Management opened 35 new positions and closed 26 in Q1 2017.
  • Sphera Funds Management's portfolio value rose 29% quarter-over-quarter to $512M.

Based on Sphera Funds Management's 13F filing for Q1 2017, filed 11 May 2017.